Mehra Uneek 4

What Happened

• Uneek Mehra, Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), received equity awards on March 10, 2026: 23,330 restricted stock units (RSUs) and 105,000 derivative awards. Both grants were reported at $0.00 per share (typical for compensation awards) and are recorded as awards/grants (Form 4 code A).

Key Details

• Transaction date and price: 2026-03-10; both awards reported at $0.00 per share.
• RSU grant: 23,330 RSUs; settle in common stock upon vesting (see F1).
• Derivative award: 105,000 units noted as a derivative award with a vesting schedule (see F2).
• Vesting schedules (from filing footnotes):
  • F1: RSUs vest in 16 equal quarterly installments over four years starting January 1, 2026; each RSU converts to one share when it vests.
  • F2: The derivative award vests monthly in 1/48th increments starting January 1, 2026.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-03-12 for transactions on 2026-03-10 (appears timely under Form 4 reporting rules).

Context

• These awards are compensation grants (not open-market purchases or sales). RSUs are contingent rights to receive shares only as they vest; derivative awards vest over time and may require exercise/settlement as specified by the plan. Such grants are commonly used for retention and incentive compensation and do not represent immediate cash proceeds or sales.